

**Supplementary Table S2. Circulating miRNA in stroke baseline patients (Males) versus healthy controls (Males).**

miRNA	Discovery		Validation		Combined	
	Log2FC <sup>1</sup>	FDR <sup>2</sup>	Log2FC <sup>1</sup>	FDR <sup>2</sup>	Log2FC <sup>1</sup>	FDR <sup>2</sup>
hsa-miR-451a	2.3	2.73 × 10 <sup>-31</sup>	2.3	1.17 × 10 <sup>-28</sup>	2.2	2.59 × 10 <sup>-64</sup>
hsa-miR-574-5p	-2.2	1.97 × 10 <sup>-15</sup>	-2.2	4.85 × 10 <sup>-21</sup>	-2.1	5.12 × 10 <sup>-43</sup>
hsa-miR-142-3p	-2.4	1.04 × 10 <sup>-38</sup>	-2.1	1.68 × 10 <sup>-31</sup>	-2.3	1.03 × 10 <sup>-83</sup>
hsa-miR-6721-5p	-2.6	6.21 × 10 <sup>-10</sup>	-2.1	4.23 × 10 <sup>-08</sup>	-2.4	4.51 × 10 <sup>-24</sup>
hsa-miR-4446-3p	-2.1	4.92 × 10 <sup>-10</sup>	-2.1	2.79 × 10 <sup>-09</sup>	-1.9	2.58 × 10 <sup>-19</sup>
hsa-miR-485-3p	-2.8	7.09 × 10 <sup>-13</sup>	-2.6	3.90 × 10 <sup>-14</sup>	-2.4	1.07 × 10 <sup>-24</sup>
hsa-miR-676-3p	-2.4	1.75 × 10 <sup>-05</sup>	-2.5	2.08 × 10 <sup>-06</sup>	-2.5	9.25 × 10 <sup>-16</sup>
hsa-miR-379-5p	-2.8	1.45 × 10 <sup>-19</sup>	-2.3	2.34 × 10 <sup>-19</sup>	-2.4	3.62 × 10 <sup>-39</sup>
hsa-miR-149-5p	-3.6	8.49 × 10 <sup>-03</sup>	-3.1	1.23 × 10 <sup>-02</sup>	-3.4	2.85 × 10 <sup>-10</sup>
hsa-miR-411-5p	-2.9	9.13 × 10 <sup>-13</sup>	-3.0	1.76 × 10 <sup>-13</sup>	-2.8	3.67 × 10 <sup>-31</sup>

<sup>1</sup>Log2 Fold Change; <sup>2</sup>False Discovery Rate